 The FDA has cleared Lyell Immunopharma Incs NASDAQ: LYEL Investigational New Drug IND application to initiate a Phase 1 trial for LYL132 in solid tumors. LYL132 is an investigational T-cell receptor TCR therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 NY-ESO-1. 